These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10552989)

  • 1. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
    Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
    J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
    Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
    Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
    Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
    J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
    Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
    J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
    Laverdiere M; Hoban D; Restieri C; Habel F
    J Antimicrob Chemother; 2002 Jul; 50(1):119-23. PubMed ID: 12096017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).
    Marco F; Danés C; Almela M; Jurado A; Mensa J; de la Bellacasa JP; Espasa M; Martínez JA; Jiménez de Anta MT
    Diagn Microbiol Infect Dis; 2003 Aug; 46(4):259-64. PubMed ID: 12944017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN; Diekema DJ
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1723-7. PubMed ID: 12019081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
    Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A
    J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of voriconazole against Mexican oral yeast isolates.
    Sánchez Vargas LO; Eraso E; Carrillo-Muñoz AJ; Aguirre JM; Gaitán-Cepeda LA; Quindós G
    Mycoses; 2010 May; 53(3):200-3. PubMed ID: 19389066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
    Pfaller MA; Messer SA; Coffman S
    Antimicrob Agents Chemother; 1997 Apr; 41(4):763-6. PubMed ID: 9087485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
    Moore CB; Oakley KL; Denning DW
    Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI; Ogbonnaya UL
    J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
    Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.